| CCN | caudal central nucleus; community care network; coronary care nursing; critical care nursing |
|---|---|
| CCU | cardiac care unit; Cherry-Crandall unit; coronary care unit; critical care unit |
| CICU | cardiac intensive care unit; cardiovascular inpatient care unit; coronary intensive care unit |
| IC | icteric, icterus; immune complex; immunoconjugate; immunocytochemistry; immunocytotoxicity; impedanc... |
| ICU | infant care unit; immunologic contact urticaria; intensive care unit; intermediate care unit |
| restriction enzyme cutting site | <molecular biology> A specific nucleotide sequence of DNA at which a particular restriction enzyme cuts the DNA. Some sites occur frequently in DNA (for example, every several hundred basepairs), others much less frequently (rare-cutter, for example, every 10,000 base pairs). (10 Mar 1998) |
|---|---|
| restriction site | A sequence in DNA that can be recognised and cut by a specific restriction enzyme. (12 Dec 1998) |
| restriction-site polymorphism | DNA polymorphism in which the sequence of one form of the polymorphism contains a recognition site for a particular endonuclease, but the sequence of the other form lacks such a site. (05 Mar 2000) |
| grade III astrocytoma | <tumour> Astrocytoma of intermediate grade. See: glioblastoma multiforme. (05 Mar 2000) |
| chi site | <molecular biology> Short, active sequences of DNA which strongly encourages crossing over of chromosomes to occur at that site. These sites become chiasmata more often than other sites. (05 Jan 1998) |
| ribosome binding site | The region of a messenger RNA molecule that binds the ribosome to initiate translation. (09 Oct 1997) |
| group III mycobacteria | Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare. Synonym: nonchromogens. (05 Mar 2000) |
| RNA polymerase III | <enzyme> A DNA-dependent RNA polymerase present in bacterial, plant, and animal cells. It functions in the nucleoplasmic structure where it transcribes DNA into RNA. It has specific requirements for cations and salt and has shown an intermediate sensitivity to alpha-amanitin in comparison to RNA polymerase I and II. Registry number: EC 2.7.7.- (12 Dec 1998) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| class III | All other perennial streams not meeting higher class criteria. (05 Dec 1998) |
| class III antigens | Non-cell membrane molecules that are encoded by the S region of the major histocompatibility complex. These antigens are not involved in determining histocompatibility and include the complement proteins. (05 Mar 2000) |
| class III malocclusion | <dentistry> A Malocclusion where your lower teeth stick out past your upper teeth. This is also called an underbite. (05 Mar 2000) |
| cleavage site | A sequence in DNA that can be recognised and cut by a specific restriction enzyme. (12 Dec 1998) |
| clinical trial, phase III | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trials, phase III | Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries. (12 Dec 1998) |